What's in a NAme?

E. Brunt

DOI: https://doi.org/10.1002/hep.23070

IF: 17.298

2009-09-01

Hepatology

Abstract:Despite sincere efforts on the parts of numerous published and unpublished individuals, myself included, the nomenclature for nonalcoholic fatty liver disease (NAFLD)/NASH has remained linked to the fact that it is a “non-association” with alcohol abuse rather than to the underlying condition(s) with which we recognize an association.1-4 Various suggestions that have been made, or could be made, include the earlier descriptors “steatofibrosis,” “fatty liver hepatitis,” and “pseudo-alcoholic fatty liver disease” and the subsequent descriptors “metabolic syndrome steatohepatitis” (MESH), “metabolic fatty liver disease,” “obesity-related fatty liver disease,” “drug-associated steatohepatitis (DASH),” and “insulin-resistance induced steatohepatitis” (IRISH). One could, of course, ponder many variations on this theme [e.g., “transplantassociated steatohepatitis” (TRASH)]; unfortunately, it seems that “NASH” is catchy and may be here to stay, much like the misnomer “primary biliary cirrhosis,” which is used for antimitochondrial antibody–positive nonsuppurative destructive cholangitis, whether it is cirrhotic or not. Many pathologists in the field have tended to agree and tried to push for a change in the nomenclature for reasons that go beyond the fact that the determination of “non– alcohol consumption” must be ultimately made by the clinician, so our diagnoses, by definition, must be purely descriptive. Perhaps more important is the fact that although the histologic features of alcoholic liver disease (ALD) do indeed cover a spectrum ranging from steatosis to steatohepatitis to cirrhosis with or without steatohepatitis, which is similar to the spectrum reported for NAFLD, ALD also includes lesions that are not present in NASH. Fundamentally, NAFLD must include steatosis, but ALD does not; alcoholic hepatitis is not uncommonly without steatosis. NAFLD would be quite rarely considered in cases of pure microvesicular steatosis; however, ALD can occur as “foamy degeneration,” in which the steatosis is entirely microvesicular steatosis.5 Other findings of ALD that are not found in the obesity-related fatty liver disease spectrum include perivenular fibrosis,6 “veno-occlusive disease–like” lesions of terminal hepatic venules,7 sclerosing hyaline necrosis,8 pericholangitis with abundant polymorphs, canalicular cholestasis, large and well-formed Mallory-Denk bodies, and often, in cirrhosis, large regions of parenchymal extinction (scar) with micronodular cirrhosis (reviewed by investigators in the field8-10). Clearly, however, the histologic features of “milder” forms of alcoholic steatosis and steatohepatitis substantially overlap those of obesity/metabolic-related steatosis/steatohepatitis, and a pathologist cannot discern the clinical diagnosis.